Liu et al. conducted a retrospective study on over 4000 patients with HER2-zero and HER2-low tumors and compared their clinical characteristics: no significant difference was found in the tumor stage at diagnosis when classifying tumors from Stage I to Stage III (p = 0.188). The gene discussed is ERBB2; the disease is neoplasm.